BTI BiOasis Technologies Inc

biOasis Technologies Inc. (TSX VENTURE:BTI) announced today an update on the
advancement of its anti-cancer product candidate BT2111. BT2111 is a
brain-penetrating conjugate of trastuzumab (Herceptin(R)) and our Transcend
vector designed to treat brain metatastsis of HER2+ breast cancer. Based on the
exceptional data announced on February 7th of this year, which show both a
remarkable reduction on brain tumors as well as tumor size, the company along
with its expert industry advisors has now developed the road map to take this
program to the next stage of preclinical development. 


"Through late 2011 and through 2012 the BT2111 program has delivered tremendous
results for biOasis," says Rob Hutchison, CEO. "The news out of Texas Technical
University announced on February 7th exceeded our expectations going into the
program. Based on these animal efficacy studies we were then in a position to
plan the balance of the pre-clinical pathway. There are a number of key studies
that we will undertake as soon as possible to further evaluate and characterize
BT2111 in order to position the program for out licensing to a pharmaceutical
partner or for further internal pre-clinical development. This work will include
additional efficacy, pharmacokinetic and safety sudies. The next efficacy study
is planned and can commence shortly and we expect to see results from this work
by mid to late summer. 


ABOUT BT2111 - BT2111 is a conjugate between biOasis' Transcend brain delivery
vector and trastuzumab (trade name of Herceptin(R)), a humanized monoclonal
antibody used clinically in the treatment of HER2+ breast cancer. It is reported
that up to 30% of HER2+ breast cancer patients develop brain metastasis for
which therapeutic options are limited. Because of its ability to cross the
blood-brain barrier, biOasis is researching the potential of BT2111 for
treatment of HER2+ metastatic breast cancer in the brain. 


Herceptin(R) is a registered trademark of Roche/Genentech. 

ABOUT BIOASIS

biOasis Technologies Inc. is a biopharmaceutical company headquartered in
Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery
platform, the Company is focused on creating new drugs that can cross the
blood-brain barrier to address unmet medical needs in the treatment of brain
diseases such as neurodegeneration, metastatic cancer and metabolic diseases.
biOasis trades on the TSX Venture Exchange under the symbol "BTI". For more
information about the Company please visit www.bioasis.ca.


Forward Looking Statements

Certain statements in this press release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that may not be based on historical fact, including without limitation
statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions. Such
forward-looking statements or information involve known and unknown risks,
uncertainties and other factors that may cause our actual results, events or
developments, or industry results, to be materially different from any future
results, events or developments express or implied by such forward-looking
statements or information. Such factors include, among others, our stage of
development, lack of any product revenues, additional capital requirements, risk
associated with the completion of clinical trials and obtaining regulatory
approval to market our products, the ability to protect our intellectual
property, dependence on collaborative partners and the prospects for negotiating
additional corporate collaborations or licensing arrangements and their timing.
Specifically, certain risks and uncertainties that could cause such actual
events or results expressed or implied by such forward-looking statements and
information to differ materially from any future events or results expressed or
implied by such statements and information include, but are not limited to, the
risks and uncertainties that: we may not be able to successfully develop and
obtain regulatory approval for p97 as a Physician's Aid to Diagnose Alzheimer's,
or future products in our targeted corporate objectives; our future operating
results are uncertain and likely to fluctuate; we may not be able to raise
additional capital; we may not be successful in establishing additional
corporate collaborations or licensing arrangements; we may not be able to
establish marketing and the costs of launching our products may be greater than
anticipated; we have no experience in commercial manufacturing; we may face
unknown risks related to intellectual property matters; we face increased
competition from pharmaceutical and biotechnology companies; and other factors
as described in detail in our filings with the Canadian securities regulatory
authorities at www.sedar.com. Given these risks and uncertainties, you are
cautioned not to place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this cautionary statement.
All forward-looking statements and information made herein are based on our
current expectations and we undertake no obligation to revise or update such
forward-looking statements and information to reflect subsequent events or
circumstances, except as required by law.


On Behalf of the Board of Directors,

Rob Hutchison, Chairman & CEO

FOR FURTHER INFORMATION PLEASE CONTACT: 
biOasis Technologies Inc.
Rob Hutchison
Chairman & CEO
(778).383.3280
rob@bioasis.ca
www.bioasis.ca

Grafico Azioni BiOasis Technologies (TSXV:BTI)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni BiOasis Technologies (TSXV:BTI)
Storico
Da Giu 2023 a Giu 2024